© 1994 Oxford University Press
OTHER |
Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTC: s
1Department of Surgery 2Department of Clinical Genetics, Karolinska Hospital S-171 76 Stockholm, Sweden
Received March 25, 1994; Accepted May 16, 1994
Since germllne mutations in the RET proto-oncogene (RET) predisposing to tumor development In Familial Medullary Thyroid Carcinoma (FMTC), Multiple endocrine neoplasia type 2A (MEN 2A), and Multiple endocrine neoplasia type 2B (MEN 2B) were reported, It has become possible to identify gene carriers with a very high degree of accuracy. Mutations in FMTC and MEN 2A exclusively affect cystelne residues in exon 10 and 11 of RET, whereas in MEN 2B codon 918 in exon 16 is involved. This latter mutation has also been described in a subset of apparently sporadic medullary thyroid carcinomas (MTC). Mutations in MEN 2B often occur as de novo germline mutations, whereas de novo mutations have not yet been described In FMTC or MEN 2A. We analyzed ten MTC: s and ten pheochromocytomas, all clinically judged to be sporadically occurring, by direct DNA sequencing of exons 10, 11, and 16 of RET. This analysis revealed a de novo germline mutation of codon 634 in exon 11 In a patient with MTC. In addition, somatic mutations of codon 918 in exon 16 in six of the remaining MTC: s were found, Interestingly, the presence of this somatic mutation was associated with a significantly less favorable clinical outcome.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. W. B. de Groot, T. P. Links, J. T. M. Plukker, C. J. M. Lips, and R. M. W. Hofstra RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine Tumors Endocr. Rev., August 1, 2006; 27(5): 535 - 560. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Jimenez, G. Cote, A. Arnold, and R. F. Gagel Should Patients with Apparently Sporadic Pheochromocytomas or Paragangliomas be Screened for Hereditary Syndromes? J. Clin. Endocrinol. Metab., August 1, 2006; 91(8): 2851 - 2858. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Cranston, C. Carniti, S. Martin, P. Mondellini, Y. Hooks, J. Leyland, S. Hodgson, S. Clarke, M. Pierotti, B. A. J. Ponder, et al. A Novel Activating Mutation in the RET Tyrosine Kinase Domain Mediates Neoplastic Transformation Mol. Endocrinol., July 1, 2006; 20(7): 1633 - 1643. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Elisei, B. Cosci, C. Romei, V. Bottici, M. Sculli, R. Lari, R. Barale, F. Pacini, and A. Pinchera RET Exon 11 (G691S) Polymorphism Is Significantly More Frequent in Sporadic Medullary Thyroid Carcinoma Than in the General Population J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3579 - 3584. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Glaser and E. W. Jabs Dear Old Dad Sci. Aging Knowl. Environ., January 21, 2004; 2004(3): re1 - re1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B E Baysal Hereditary paraganglioma targets diverse paraganglia J. Med. Genet., September 1, 2002; 39(9): 617 - 622. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Niccoli-Sire, A. Murat, V. Rohmer, S. Franc, G. Chabrier, L. Baldet, B. Maes, F. Savagner, S. Giraud, S. Bezieau, et al. Familial Medullary Thyroid Carcinoma with Noncysteine RET Mutations: Phenotype-Genotype Relationship in a Large Series of Patients J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3746 - 3753. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Wiench, Z. Wygoda, E. Gubala, J. Wloch, K. Lisowska, J. Krassowski, D. Scieglinska, A. Fiszer-Kierzkowska, D. Lange, D. Kula, et al. Estimation of Risk of Inherited Medullary Thyroid Carcinoma in Apparent Sporadic Patients J. Clin. Oncol., March 1, 2001; 19(5): 1374 - 1380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Quadro, O. Fattoruso, M. P. Cosma, U. Verga, A. Porcellini, A. Libroia, and V. Colantuoni Loss of Heterozygosity at the RET Protooncogene Locus in a Case of Multiple Endocrine Neoplasia Type 2A J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 239 - 244. [Abstract] [Full Text]
|
|
|
|
|
|
C. Eng RET Proto-Oncogene in the Development of Human Cancer J. Clin. Oncol., January 1, 1999; 17(1): 380 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Sánchez, M. Robledo, J. Biarnes, M.-E. Sáez, V. Volpini, J. Benítez, E. Navarro, A. Ruiz, G. Antiñolo, and S. Borrego High prevalence of the C634Y mutation in the RET proto-oncogene in MEN 2A families in Spain J. Med. Genet., January 1, 1999; 36(1): 68 - 70. [Abstract] [Full Text]
|
|
|
|
|
|
D. J. Marsh, Z. Zheng, A. Arnold, S. D. Andrew, D. Learoyd, A. Frilling, P. Komminoth, H. P.H. Neumann, B. A.J. Ponder, B. J. Rollins, et al. Mutation Analysis of Glial Cell Line-Derived Neurotrophic Factor, a Ligand for an RET/Coreceptor Complex, in Multiple Endocrine Neoplasia Type 2 and Sporadic Neuroendocrine Tumors J. Clin. Endocrinol. Metab., September 1, 1997; 82(9): 3025 - 3028. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Eng The RET Proto-Oncogene in Multiple Endocrine Neoplasia Type 2 and Hirschsprung's Disease N. Engl. J. Med., September 26, 1996; 335(13): 943 - 951. [Full Text] [PDF]
|
|